Condition: Heart Failure - NYHA II - IV · Sponsor: University of Leipzig
PEDAL-HF is a registry-based randomized prospective multicenter study. The investigators plan to include 1000 patients who were recently admitted with acute decompensated heart failure at five tertiary heart clinics in Germany. For the randomised part, 750 patients will be randomized to care within a heart failure network or usual care. The primary endpoint of the randomized trial is change in NT-proBNP from baseline to 6 months of follow-up. All patients (randomized or not) will be followed for two years.
This description comes directly from the study's public registry record.
Rolf Wachter, MD · +49-341-97-12650 · rolf.wachter@medizin.uni-leipzig.de
Sophie Charlotte Schröder, MD · +49-341-97-12650 · sophiecharlotte.schroeder@medizin.uni-leipzig.de
Always discuss trial participation with your own doctor first.
| University Hospital Leipzig | Leipzig, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06656832